^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TrkA receptor antagonist

    Related drugs:
    1d
    TRUST-I: A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (clinicaltrials.gov)
    P2, N=173, Active, not recruiting, Nuvation Bio Inc. | Trial completion date: Dec 2025 --> Jun 2027
    Trial completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Ibtrozi (taletrectinib)
    17d
    AB-106-C205: Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (clinicaltrials.gov)
    P2, N=14, Terminated, Nuvation Bio Inc. | N=40 --> 14 | Recruiting --> Terminated; The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
    Enrollment change • Trial termination • Pan tumor
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Ibtrozi (taletrectinib)
    2ms
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    3ms
    Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib. (PubMed, Zhongguo Ying Yong Sheng Li Xue Za Zhi)
    Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases. These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.
    Review • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 positive
    |
    Ibtrozi (taletrectinib)
    4ms
    TRUST-II: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (clinicaltrials.gov)
    P2, N=217, Active, not recruiting, Nuvation Bio Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Ibtrozi (taletrectinib)
    4ms
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New trial • Real-world evidence
    |
    Rozlytrek (entrectinib) • Ibtrozi (taletrectinib)
    5ms
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) (clinicaltrials.gov)
    P3, N=180, Recruiting, Nuvation Bio Inc.
    New P3 trial
    |
    Ibtrozi (taletrectinib)
    7ms
    Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Ibtrozi (taletrectinib)